skip to content

Cambridge Cardiovascular



I am a clinician-scientist and Honorary Consultant Rheumatologist at Addenbrooke's Hospital in Cambridge and at Barts Health NHS Trust in London, with a specialist clinical practice in vasculitis.

I am interested in the interface of inflammation and cardiovascular diseases and in using genomic technologies to better understand the pathogenesis of cardiovascular diseases in humans. Unusually for a clinician, I have a strong quantitative and computational background (MPhil in Computational Biology and PhD in genomics from the University of Cambridge).

The importance of inflammation in cardiovascular diseases is now well established. Accelerated atherosclerosis is a feature of many of the autoimmune rheumatic diseases, and a better understanding of vascular inflammation is key to developing new therapies for atherosclerosis and for vasculitis.

Against this background, my research focuses on gaining insight into the aetiology of cardiovascular diseases and vascular inflammation by applying –omic (particularly proteomic) technologies at the population level. An important approach is the use of Mendelian randomisation to identify likely causal mediators of cardiovascular diseases which may be amenable to therapeutic intervention.


Key publications: 

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. JAMA Cardiol. 2018 Jun 20. doi: 10.1001/jamacardio.2018.1470. [Epub ahead of print]

Genomic atlas of the human plasma proteome. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, Oliver-Williams C, Kamat MA, Prins BP, Wilcox SK, Zimmerman ES, Chi A, Bansal N, Spain SL, Wood AM, Morrell NW, Bradley JR, Janjic N, Roberts DJ, Ouwehand WH, Todd JA, Soranzo N, Suhre K, Paul DS, Fox CS, Plenge RM, Danesh J, Runz H, Butterworth AS. Nature. 2018 Jun;558(7708):73-79.

Targeted genomic analysis reveals widespread autoimmune disease association with regulatory variants in the TNF superfamily cytokine signalling network. Richard AC, Peters JE, Lee JC, Vahedi G, Schäffer AA, Siegel RM, Lyons PA, Smith KG. Genome Med. 2016 Jul 19;8(1):76.

Insight into Genotype-Phenotype Associations through eQTL Mapping in Multiple Cell Types in Health and Immune-Mediated Disease. Peters JE, Lyons PA, Lee JC, Richard AC, Fortune MD, Newcombe PJ, Richardson S, Smith KG. PLoS Genet. 2016 Mar 25;12(3):e1005908.

MT-HESS: an efficient Bayesian approach for simultaneous association detection in OMICS datasets, with application to eQTL mapping in multiple tissues. Lewin A, Saadi H, Peters JE, Moreno-Moral A, Lee JC, Smith KG, Petretto E, Bottolo L, Richardson S. Bioinformatics. 2016 Feb 15;32(4):523-32.

Comparison of gene expression microarray data with count-based RNA measurements informs microarray interpretation. Richard AC, Lyons PA, Peters JE, Biasci D, Flint SM, Lee JC, McKinney EF, Siegel RM, Smith KG. BMC Genomics. 2014 Aug 4;15:649.

BHF Career Development Fellow, University of Cambridge
UKRI Innovation Fellow at Health Data Research (HDR) UK
Dr James  Peters